Answers are grounded in this paper and cite their sources.
Recurrent aphthous stomatitis lacks safe targeted therapies, as routine treatments only relieve symptoms with side effects. We developed Syl3c-EpCAM aptamer-modified artichoke extracellular vesicles (Apt@Cs-EVs) for oral epithelial targeted delivery and clarified their antiulcer mechanisms. Characterizations confirmed intact-vesicle morphology, stable colloidal performance, and noncytotoxicity; Apt@Cs-EVs efficiently entered oral keratinocytes through Syl3c-EpCAM specific binding. Mechanistically, Apt@Cs-EVs curb iNOS-triggered NO overproduction, mitigate Akt S-nitrosylation, restore Akt Ser473 phosphorylation, and activate cNOS signaling. This pathway elevates mucins and tight junction proteins to reconstruct mucosal barriers, while blocking NF-κB to reduce inflammatory cytokines and neutrophil infiltration. In mouse ulcer models, topical Apt@Cs-EVs achieve faster mucosal repair than unmodified vesicles and triamcinolone acetonide, with no systemic toxicity validated by blood, hepatorenal, and tissue pathological tests. This study first uncovers the core role of the iNOS/NO/Akt/cNOS axis in ulcer healing, offering a safe, effective targeted plant nanomedicine for RAS clinical management.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: